Effect of phenylhexyl isothiocyanate on aberrant histone H3 methylation in primary human acute leukemia
Open Access
- 2 July 2012
- journal article
- research article
- Published by Springer Nature in Journal of Hematology & Oncology
- Vol. 5 (1) , 36
Abstract
Background: We have previously studied the histone acetylation in primary human leukemia cells. However, histone H3 methylation in these cells has not been characterized. Methods: This study examined the methylation status at histone H3 lysine 4 (H3K4) and histone H3 lysine 9 (H3K9) in primary acute leukemia cells obtained from patients and compared with those in the non-leukemia and healthy cells. We further characterized the effect of phenylhexyl isothiocyanate (PHI), Trichostatin A (TSA), and 5-aza-2’-deoxycytidine (5-Aza) on the cells. Results: We found that methylation of histone H3K4 was virtually undetectable, while methylation at H3K9 was significantly higher in primary human leukemia cells. The histone H3K9 hypermethylation and histone H3K4 hypomethylation were observed in both myeloid and lymphoid leukemia cells. PHI was found to be able to normalize the methylation level in the primary leukemia cells. We further showed that PHI was able to enhance the methyltransferase activity of H3K4 and decrease the activity of H3K9 methyltransferase. 5-Aza had similar effect on H3K4, but minimal effect on H3K9, whereas TSA had no effect on H3K4 and H3K9 methyltransferases. Conclusions: This study revealed opposite methylation level of H3K4 and H3K9 in primary human leukemia cells and demonstrated for the first time that PHI has different effects on the methyltransferases for H3K4 and H3K9.Keywords
This publication has 38 references indexed in Scilit:
- Novel targeted therapeutics: inhibitors of MDM2, ALK and PARPJournal of Hematology & Oncology, 2011
- Targeted therapy in lymphomaJournal of Hematology & Oncology, 2010
- Novel agents and regimens for acute myeloid leukemia: 2009 ASH annual meeting highlightsJournal of Hematology & Oncology, 2010
- From basic research to clinical development of MEK1/2 inhibitors for cancer therapyJournal of Hematology & Oncology, 2010
- Novel histone deacetylase inhibitors in clinical trials as anti-cancer agentsJournal of Hematology & Oncology, 2010
- New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancerJournal of Hematology & Oncology, 2009
- Phenylhexyl isothiocyanate has dual function as histone deacetylase inhibitor and hypomethylating agent and can inhibit myeloma cell growth by targeting critical pathwaysJournal of Hematology & Oncology, 2008
- Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancerNature Genetics, 2005
- Translating the Histone CodeScience, 2001
- The language of covalent histone modificationsNature, 2000